IP Library › Patent Application 13212847
Patent Application
App. No. 13/212,847

HLA-A2 TUMOR ASSOCIATED ANTIGEN PEPTIDES AND COMPOSITIONS

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
13/212,847
Abstract

A peptide or composition comprising at least one HLA-A2 epitope or analog from CEA, HER2/neu, MAGE2, MAGE3, or p53.

Claims (87)

1 - 14 . (canceled)

15 . A composition comprising a peptide comprising a cytotoxic T-cell lymphocyte (CTL) epitope KVFGSLAFV (SEQ ID NO: 7) and a peptide comprising a cytotoxic T-cell lymphocyte (CTL) epitope YLSGADLNL (SEQ ID NO:8), each peptide being less than 15 amino acid residues in length, and the composition further comprising at least three additional peptides, wherein each of said three peptides is less than 15 amino acid residues in length and comprises a cytotoxic T-cell lymphocyte (CTL) epitope and/or analog selected from the group consisting of

KLBPVQLWV,

(SEQ ID NO: 6)

SMPPPGTRV,

(SEQ ID NO: 5)

IMIGHLVGV,

(SEQ ID NO: 9)

LLTFWNPPV,

(SEQ ID NO: 4)

KVAEIVHFL,

(SEQ ID NO: 10)

RLLQETELV,

(SEQ ID NO: 2)

and

YLQLVFGIEV.

(SEQ ID NO: 3)

16 . A composition of claim 15 , further comprising a fourth peptide, wherein said fourth peptide is less than 15 amino acid residues in length and comprises a cytotoxic T-cell lymphocyte (CTL) epitope and/or analog selected from the group consisting of

KLBPVQLWV,

(SEQ ID NO: 6)

SMPPPGTRV,

(SEQ ID NO: 5)

IMIGHLVGV,

(SEQ ID NO: 9)

LLTFWNPPV,

(SEQ ID NO: 4)

KVAEIVHFL,

(SEQ ID NO: 10)

RLLQETELV,

(SEQ ID NO: 2)

and

YLQLVFGIEV.

(SEQ ID NO: 3)

17 . A composition of claim 16 , further comprising a fifth peptide, wherein said fifth peptide is less than 15 amino acid residues in length and comprises a cytotoxic T-cell lymphocyte (CTL) epitope and/or analog selected from the group consisting of

KLBPVQLWV,

(SEQ ID NO: 6)

SMPPPGTRV,

(SEQ ID NO: 5)

IMIGHLVGV,

(SEQ ID NO: 9)

LLTFWNPPV,

(SEQ ID NO: 4)

KVAEIVHFL,

(SEQ ID NO: 10)

RLLQETELV,

(SEQ ID NO: 2)

and

YLQLVFGIEV.

(SEQ ID NO: 3)

18 . A composition of claim 17 , further comprising a sixth peptide, wherein said sixth peptide is less than 15 amino acid residues in length and comprises a cytotoxic T-cell lymphocyte (CTL) epitope and/or analog selected from the group consisting of

KLBPVQLWV,

(SEQ ID NO: 6)

SMPPPGTRV,

(SEQ ID NO: 5)

IMIGHLVGV,

(SEQ ID NO: 9)

LLTFWNPPV,

(SEQ ID NO: 4)

KVAEIVHFL,

(SEQ ID NO: 10)

RLLQETELV,

(SEQ ID NO: 2)

and

YLQLVFGIEV.

(SEQ ID NO: 3)

19 . A composition of claim 18 , further comprising a seventh peptide, wherein said seventh peptide is less than 15 amino acid residues in length and comprises a cytotoxic T-cell lymphocyte (CTL) epitope and/or analog selected from the group consisting of

KLBPVQLWV,

(SEQ ID NO: 6)

SMPPPGTRV,

(SEQ ID NO: 5)

IMIGHLVGV,

(SEQ ID NO: 9)

LLTFWNPPV,

(SEQ ID NO: 4)

KVAEIVHFL,

(SEQ ID NO: 10)

RLLQETELV,

(SEQ ID NO: 2)

and

YLQLVFGIEV.

(SEQ ID NO: 3)

20 . A composition according to claim 15 , further comprising an additional peptide, wherein said additional peptide is less than 25 amino acid residues in length and comprises a helper T lymphocyte (HTL) epitope.

21 . A composition according to claim 20 , wherein said additional peptide is a pan-DR binding peptide.

22 . A composition according to claim 21 , wherein said pan-DR binding peptide comprises the amino acid sequence aKXVAAWTLKAAa (SEQ ID NO:1).

23 . A composition according to claim 15 , further comprising a liposome.

24 . A composition according to claim 15 , further comprising a lipid.

25 . A composition according to claim 15 , further comprising a pharmaceutical excipient.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 31, 2014
From: BIOTECH SYNERGY, INC.
To: OSE PHARMA INTERNATIONAL SA
Reel/Frame 033453/0211 →